Clinical Trials · NCT00516048
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 58
- Start date
- Aug 2007
- Locations
- 13 sites, 5 countries
- Primary endpoint
- Treatment-emergent Antibody Status (Maximum Titer Level Experienced)